Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara Valpione

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2018
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective studySara Valpione, Matteo S Carlino, Johanna Mangana, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 24, 2024
Treatment strategies with electrochemotherapy for limb in-transit melanoma: Real-world outcomes from a European, retrospective, cohort studyLuca G Campana, Francesca Tauceri, Joana Bártolo, et al.
European Journal of Cancer (Oxford, England : 1990)|February 27, 2022
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver J Kennedy, Michal Kicinski, Sara Valpione, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2023
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver John Kennedy, Michal Kicinski, Sara Valpione, et al.
European Journal of Cancer (Oxford, England : 1990)|February 25, 2024
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver John Kennedy, Nina Glassee, Michal Kicinski, et al.
The British Journal of Surgery|May 3, 2023
European e-Delphi process to define expert consensus on electrochemotherapy treatment indications, procedural aspects, and quality indicators in melanomaLuca G Campana, Sofia Farronato, Jackie Hodgetts, et al.
Nature Medicine|March 1, 2022
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanomaKarla A Lee, Andrew Maltez Thomas, Laura A Bolte, et al.
Nature Medicine|February 16, 2024
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanomaJohannes R Björk, Laura A Bolte, Andrew Maltez Thomas, et al.
Journal for Immunotherapy of Cancer|May 23, 2019
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshopDavide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, et al.
Journal for Immunotherapy of Cancer|July 6, 2019
Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshopDavide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2018
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective studySara Valpione, Matteo S Carlino, Johanna Mangana, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 24, 2024
Treatment strategies with electrochemotherapy for limb in-transit melanoma: Real-world outcomes from a European, retrospective, cohort studyLuca G Campana, Francesca Tauceri, Joana Bártolo, et al.
European Journal of Cancer (Oxford, England : 1990)|February 27, 2022
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver J Kennedy, Michal Kicinski, Sara Valpione, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2023
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver John Kennedy, Michal Kicinski, Sara Valpione, et al.
European Journal of Cancer (Oxford, England : 1990)|February 25, 2024
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver John Kennedy, Nina Glassee, Michal Kicinski, et al.
The British Journal of Surgery|May 3, 2023
European e-Delphi process to define expert consensus on electrochemotherapy treatment indications, procedural aspects, and quality indicators in melanomaLuca G Campana, Sofia Farronato, Jackie Hodgetts, et al.
Nature Medicine|March 1, 2022
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanomaKarla A Lee, Andrew Maltez Thomas, Laura A Bolte, et al.
Nature Medicine|February 16, 2024
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanomaJohannes R Björk, Laura A Bolte, Andrew Maltez Thomas, et al.
Journal for Immunotherapy of Cancer|May 23, 2019
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshopDavide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, et al.
Journal for Immunotherapy of Cancer|July 6, 2019
Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshopDavide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, et al.
Pageof 5